当地时间3月29日至31日，第74届美国心脏病学会科学年会（ACC.25）即将在美国芝加哥盛大召开。本届年会共设置了6个最新突破性临床试验（Late-Breaking Clinical Trials，LBCTS）专场、5个特色临床研究（Featured Clinical Research，FCR）专场、2个临床和研究视野（Clinical and Investigative Horizons）和2个最新突破性临床试验深入探究（Late-Breaking Clinical Trial Deep Dive）专场等多场精彩会议。其中，FCR专场即将公布20项最新试验成果，临床和研究视野即将公布10项临床研究结果，本文带您先睹为快！

作者：Xuemei Guo

一、特色临床研究专场

1. Featured Clinical Research I (Session 109)

北京时间：3月31日, 02:30-03:30

当地时间：Sunday, March 30, 1:30 – 2:30 p.m. CT

会议地点：Main Tent, North Hall B

1）Pre-Operative Treatment With Digifab Prevents Post-Operative Acute Kidney Injury (AKI) in Patients at High Risk For AKI Undergoing Cardiac Bypass Graft Surgery

术前使用Digifab进行治疗，可预防心脏搭桥术后高危患者的急性肾损伤（AKI）

讲者：Stephen Gottlieb

2）Catheter Ablation Vs. Risk Factor Modification With Antiarrhythmic Drugs to Treat Atrial Fibrillation: PRAGUE-25 Study

PRAGUE-25试验：对比导管消融或抗心律失常药物在改变危险因素治疗房颤中的疗效

讲者：Pavel Osmancik

3）An Extended Duration Small-Interfering RNA Targeting Lipoprotein(a): The Alpaca Phase 2 Trial of Lepodisiran With 540 Day Follow-Up

Alpaca 2期试验随访540天的结果：一种靶向lp (a)的长效小干扰RNA类药物lepodisiran的疗效

讲者：Steven Nissen

4）Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: The Detect AS Trial

Detect AS试验：应用电子医疗服务提供者通知，促进严重主动脉瓣狭窄的识别和管理

讲者：Sammy Elmariah

2. Featured Clinical Research II (Session 110)

北京时间：3月31日, 04:30-05:30

当地时间：Sunday, March 30, 3:30 – 4:30 p.m. CT

会议地点：Main Tent, North Hall B

1）Herzcheck - Mobile CMR to Improve Subclinical Heart Failure Detection in Rural Areas

Herzcheck试验：应用移动CMR改善农村地区亚临床心衰的检测

讲者：Sebastian Ulrich Kelle

2）A Double Blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients With HFrEF: Principal Results From the CardiAMP-HF Trial

CardiAMP-HF双盲随机对照试验的主要结果：自体细胞疗法在射血分数降低的心衰（HFrEF）患者中的疗效

讲者：Amish Raval

3）Early Intra-aortic Balloon Pump in Heart Failure Complicated by Cardiogenic Shock: The Altshock-2 Randomized Clinical Trial

Altshock-2随机临床试验：早期主动脉内球囊反搏泵治疗心衰合并心源性休克的疗效

讲者：Alice Sacco

4）Health 360x.ai Registry: AI Enabled Equitable Access To Point of Care Decentralized Clinical Trials

Health 360x.ai注册试验：人工智能使得公平参与即时护理分散式临床试验成为可能

讲者：Elizabeth Ofili

3. Featured Clinical Research III (Session 111)

北京时间：3月31日, 06:00-07:00

当地时间：Sunday, March 30, 5 – 6 p.m. CT

会议地点：Main Tent, North Hall B

1）Modified Application of Cardiac Rehabilitation For Older Adults (MACRO)

老年人心脏康复的改良应用（MACRO）

讲者：Daniel Forman

2）Survival Outcomes After Sudden Cardiac Arrest in Young Competitive Athletes From the United States

美国年轻竞技运动员心脏性骤停的生存结局

讲者：Bradley Petek

3）Lifetime Benefit by Control of Modifiable Risk Factors

通过控制可修饰危险因素所带来的终生获益

讲者：Christina Magnussen

4）Cardiac Arrest During Long-Distance Running Races: 2010-2023

2010-2023年，长跑比赛中的心脏骤停

讲者：Jonathan Kim

4. Featured Clinical Research IV (Session 112)

北京时间：3月31日 22:00-23:00

当地时间：Monday, March 31, 9 – 10 a.m. CT

会议地点：Main Tent, North Hall B

1）Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction, Obesity and Chronic Kidney Disease: The Summit Trial

SUMMIT试验：Tirzepatide在射血分数保留的心衰（HFpEF）合并肥胖和慢性肾脏病患者中的应用

讲者：Milton Packer

2）Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared To Placebo: The Ekstrom Trial

Ekstrom试验：在稳定型冠脉疾病患者中，探究秋水仙碱与安慰剂相比对已知冠状动脉粥样硬化进展的影响

讲者：Matthew Budoff

3）Effects of Dapagliflozin on Echocardiographic Measures of Cardiac Structure and Function in Patients With Chronic Kidney Disease: The DECODE-CKD Trial

DECODE-CKD试验：达格列净对慢性肾脏病患者心脏结构和功能超声心动图指标的影响

讲者：Katja Vu Bartholdy

4）Effect of Solbinsiran, a Small Interfering RNA Targeting ANGPTL3, on Biomarkers of Major Adverse Cardiovascular Events in Adults With Mixed Dyslipidemia: A Randomized Phase 2 Trial

一项随机2期试验：靶向ANGPTL3的小干扰RNA药物Solbinsiran对混合型血脂异常成人主要心血管不良事件生物标志物的影响

讲者：Kausik Ray

5. Featured Clinical Research V (Session 113)

北京时间：4月1日 00:00-01:00

当地时间：Monday, March 31, 11 a.m. – Noon CT

会议地点：Main Tent, North Hall B

1）New Insights From the Early and Delayed Aortic Valve Replacement Implant Patients: A Sub-Analysis of the Early TAVR Trial

Early TAVR试验亚组分析：早期和延迟经导管主动脉瓣置换术（TAVR）植入患者的新发现

讲者：Philippe Genereux

2）Alternative Antithrombotic Pathways in Acute Myocardial Infarction With Large Thrombus Burden: A Randomized Trial ARISE-ARMYDA 7

ARISE-ARMYDA 7随机试验：血栓负荷大的急性心梗患者的替代抗血栓途径

讲者：Marco Mennuni

3）Efficacy and Safety of Azd0780, an Oral Small Molecule PCSK9 Inhibitor For Treatment of Hypercholesterolemia: Results From a Ph2b Randomized Placebo-Controlled Clinical Trial

2b期随机安慰剂对照临床试验结果：口服小分子PCSK9抑制剂Azd0780治疗高胆固醇血症的疗效和安全性

讲者：Michael Koren

4）Effectiveness of the 0/1-hour Algorithm For Chest Pain Assessment in Patients Presenting to the Emergency Department: A Multicenter Study in Asian Countries

亚洲多中心试验：0/1h算法在急诊患者胸痛评估中的有效性

讲者：Kenji Inoue

二、临床和研究视野专场

1. Clinical and Investigative Horizons I (Session 402)

北京时间：3月31日,22:00-23:00

当地时间：Monday, March 31, 9–10 a.m. CT

会议地点：S100bc

1）First Report of Phase Ib/2a Study Evaluating Safety and Early Efficacy of Tn-201, An Adeno-Associated Virus Serotype 9 Gene Replacement Therapy, In Adults With Mybpc3-Associated Hypertrophic Cardiomyopathy

Ib/2a期试验首次报告了Tn-201(一种基于腺相关病毒血清型9的基因疗法)在MYBPC3相关肥厚型心肌病成人患者中的安全性和早期疗效

讲者：Milind Desai

2）Artificial Intelligence-Based Quantitative Computed Tomography (AI QCT) Coronary Plaque Features Predict Risk More Pronounced in Females: The International Multicentric Registry Confirm2 (Coronary CT Angiography Evaluation For Evaluation of Clinical Outcomes)

CONFIRM2国际多中心试验（冠脉CT血管造影评估临床结果），基于人工智能的定量计算机断层扫描（AI QCT）冠脉斑块特征预测女性风险更为明显

讲者：Gudrun Feuchtner

3）Effect of Berberine Hydrochloride on Visceral and Liver Fat in Non-Diabetic Individuals With Visceral Adiposity

盐酸小檗碱对非糖尿病患者内脏型肥胖患者内脏脂肪和肝脏脂肪的影响

讲者：Lubi Lei

4）Artificial Intelligence Empowers Novice Users to Acquire Diagnostic-Quality Echocardiography

人工智能使新用户能够获得高诊断质量的超声心动图

讲者：Bertrand Moal

5）Efficacy and Safety of Sotatercept in High-Risk Patients With Pulmonary Arterial Hypertension: Results From ZENITH Phase 3 Trial

ZENITH 3期试验结果：Sotatercept在肺动脉高压高危患者中的有效性和安全性

讲者：Marc Humbert

2. Clinical and Investigative Horizons II (Session 434)

北京时间：4月01日,02:00-03:00

当地时间：Monday, March 31,1 – 2 p.m. CT

会议地点：S100bc

1）Efficacy and Safety of SHR-1918, an Angiopoietin-like 3 Monoclonal Antibody, in Combination With Lipid-Lowering Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Multicenter, Randomized, Double Blind, Placebo-Controlled Phase 2 Trial

一项多中心、随机、双盲、安慰剂对照2期试验：血管生成素样蛋白3的单克隆抗体SHR-1918与降脂治疗联合应用对控制欠佳的高脂血症患者的疗效和安全性

讲者：Xiaojie Xie

2）Homogeneous Effects of Intensive Blood Pressure Control in Patients With Various Frailty Status: A Post-hoc Analysis of the Esprit Trial

Esprit试验事后分析：不同虚弱状态患者强化降压治疗的同质效应

讲者：Shitian Li

3）Impact of Intravascular Imaging Guidance on Percutaneous Coronary Intervention of Severely Calcified Lesions: The ECLIPSE Trial

ECLIPSE试验：血管内成像引导对严重钙化病变经皮冠状动脉介入治疗的影响

讲者：Gregg Stone

4）A Randomized Controlled Crossover Study of Cardiologist Reporting of Severe Aortic Stenosis With and Without Assistance From Artificial Intelligence (AI)

在AI辅助和不辅助的情况下，心脏病学专家报告严重主动脉瓣狭窄的随机对照交叉研究

讲者：David Playford

5）Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Primary Biomarker Analysis From the EARLY TAVR TrialEarly 

TAVR试验的主要生物标志物分析：无症状严重主动脉瓣狭窄患者的心脏生物标志物

讲者：Brian Lindman